A photo showing the logo of the Swiss pharmaceutical giant Roche in Basel.
Sebastien Bozon | AFP | Pictures of getty
Swiss pharmaceutical giant Roche Tuesday he said That would invest $ 50 billion in the United States for the next five years, amid concern about the impact of possible new white house rates on foreign pharmaceutical merchandise.
The investment will create more than 12,000 jobs, Roche said: 1,000 with the company and the rest to support the new north -American manufacturing capabilities. The firm said that it already employs more than 25,000 people in America.
Roche’s shares were 1.1% lower at 8:39 AM in London.
The pharmaceutical giant will inject cash to create new state -of -the -art research and development sites (R&D), while strengthening and expanding manufacturing facilities in Indiana, Pennsylvania, Massachusetts and California. A new R&D site in Massachusetts will be used for AI research and will act as a research center on cardiovascular, renal and metabolism treatments.
The financing package will also be used to build a new 900,000 square feet in an unknown place to support the « Roche expanding portfolio of weight loss medicines for the next generation ».
Once the new manufacturing capacity investments were completed, Roche said that he would export more medicines in the United States than.
Pharmaceutical companies have been searching to strengthen their presence in the United States in the midst threats of President Donald Trump to end the exemption from the import rate industry.
« We will be announcing a major rate about pharmaceuticals very soon, » he said at the beginning of this month.
Roche’s investment follows similar movements of the main rivals. Earlier this month, Novartis de Switzerland announced Plans for investing $ 23 billion in creation and expanding 10 North -American facilities, in a movement that said it would create more than 4,000 jobs.
British pharmaceutical giant Astrazeneca Last Arna he said that would invest $ 2.5 billion in creating a Beijing center. However, the company’s CEO, Pascal Soriot, told CNBC at that time that Astrazeneca remained « very committed to the United States », where he has two « very large » research and research centers.
Roche’s CEO Thomas Schinecker said on Tuesday in a statement that the company’s new $ 50 billion investment demonstrated its « long -term commitment to research, development and manufacturing in the United States. »
« We are proud of our 110 -year legacy in the United States, which has been a key engine for jobs, innovation and intellectual property creation in the United States, in our pharmaceutical and diagnostic divisions, » he said. « Our $ 50 billion investments over the next five years will be the foundations for our next era of innovation and growth, benefiting patients in the United States and all over the world. »
Leave a Reply